NorthWest Biotherapeutics Inc (NWBO)

[gpb]

Among the various interesting details in that study, I can't help but focus on the differential response analysis. Yet again, a study demonstrates how critically important it is to target ALL the antigens expressed (or as many as possible) by a patient's cancer. SCIB1 is based on TRP-2 and gp100, and while it was remarkably effective against most of her tumors, it was useless against the metastasis that didn't express gp100 (fortunately it was surgically resectable). Which brings us right back to NWBO and how neither DCVax-L nor DCVax-Direct is initially limited to one or a few antigens, instead picking up whatever signal is available. It might be less efficient but the approach seems to be fundamentally more resilient in the face of a highly adaptive enemy.

As difficult as it is to remain patient with the NWBO timeline, studies like this from other (competing even) companies validating NWBO's core premise/differentiation really help pass the time in an encouraging way.

Thanks for yet another enlightening post.